anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators propose to develop and pilot a brief combination intervention which addresses the key drivers of alcohol use and barriers to HIV care engagement and ART adherence in this population. This study addresses these multi-level factors in an intervention which combines a structural component of changing the mode of work payments from cash to mobile money, to reduce "cash in the pocket," and increase the accessibility of savings through mobile phone-based banking services, with behavioral components to change behavior. For the behavioral components, the study combines and adapt two efficacious Motivational Interviewing (MI)-based alcohol interventions to the cultural and situational context of this population: a brief intervention tested in Kenya and an intervention rooted in behavioral economics which focuses on increasing the extent to which individuals' behavior is motivated by and consistent with their long-term goals such as saving money for the future-in which the structural component of the intervention is interwoven. The aims of the project are to: 1) Combine a promising structural (e.g., reducing "cash in the pocket") and behavioral intervention to promote reductions in heavy alcohol use, engagement in HIV care, and ART adherence among HIV+ male fisherfolk. These interventions will be adapted and tailored to the population to create the proposed KISOBOKA ("It is possible!") intervention. The investigators will refine the combination intervention through qualitative research with HIV+ male fisherfolk and community stakeholders and an initial pilot test with 15 participants examining acceptability and feasibility; 2) Pilot the intervention, randomizing to the KISOBOKA intervention arm (n=80) or to the control arm (n=80, alcohol screening and referral). The investigators will assess feasibility, acceptability, and preliminary estimates of the potential for the intervention, as compared to control, to decrease heavy drinking frequency and improve HIV care engagement and ART adherence through 6 month follow up.
Participant's first study visit involved 25 minutes of interaction with the participant's pet dog. The second study visit involved 25 minutes of individual play with toys. The third study visit involved 25 minutes of interaction with an unfamiliar dog.
Disclosure is related to a method for storing medical images, and a related imaging system. The system retrieves original serial image data of an organism body from a medical modality. A three-dimensional image can be rebuilt from the image data and allowing an operator to process reviewing. The system then collects operating signals from the process of reviewing. One or more images of critical profile can be determined based on the operating signals. After that, image information respectively associated with the images of critical profiles and non-critical profiles is obtained for rendering different tactics for separately storing the images of the critical and non-critical profiles. For example, the images for the critical profiles are stored as the original images; and the images for the non-critical profiles are stored using a streamlined scheme. The storing method effectively reduces the storage space.
NEW MATERIAL:A compound shown by formula I [R1 is H or CH3; group shown by formula II is single bond (in this case R2 is aryl, aralkyl, heteroaryl, etc.; X-A is case where X is O or NH and A is aryl or X is O or S and A is alkyl, aralkyl, alkenyl, etc.) or unsaturated double bond (in this case R2 is H, alkyl, alkenyl, alkynyl, etc.; X is S; A is alkyl, aralkyl, alkenyl, etc.)], its pharmaceutically acceptable ester, amide or salt. EXAMPLE:4-[1-Phenyl-2-(imidazol-1-yl)ethylthio]butyric acid methyl ester. USE:A remedy for circulatory diseases resulting from thromboxane A2. PREPARATION:A compound shown by formula III is reacted with a compound shown by formula IV (R2 and X-A are the above-mentioned groups when group shown by formula II is single bond; W is eliminable group; R3 is H or carboxyl- protecting group) and optionally the protecting group is removed to give a compound shown by formula V among compounds shown by formula I.
The invention provides a natural immune activation nano-drug which consists of a metal-organic framework-801 (MOF-801), cytosine-guanine phosphate oligonucleotides (CpG ODNs) and 5, 6-dimethylxanthine-4-acetic acid (DMXAA). The particle size of the immune nano-drug is 50-800 nanometers, and the immune nano-drug is in an octahedral shape. The invention also provides a preparation method of the natural immune activation nano-drug, application of the natural immune activation nano-drug in treating cancers and application of the natural immune activation nano-drug as a drug carrier. The metal-organic frameworks-801 of the present invention can be used as stimulators of the interferon gene (STING) by Toll-like receptor 4 (TLR 4) in addition to drug delivery vehicles; meanwhile, the STING agonist CpG ODNs and the DMXAA are coordinated with the MOF-801 to be assembled into the natural immune activation nano-drug. The natural immune activation nano-drug can efficiently load and deliver CpG ODNs and DMXAA, and promote dendritic cell maturation and destroy tumor blood vessels to synergistically improve tumor microenvironment by differentiating tumor-related macrophages into M1 type. The preparation method is simple and convenient, and is suitable for large-scale production.
PURPOSE: An antibody for TLT(TREM-like transcript)-6 protein is provided to diagnose, prevent, and treat hypersensitivity immune diseases. CONSTITUTION: An antibody for TLT-6 is conjugated to a peptide of sequence number 7. TLT-6 has an amino acid sequence of sequence number 1. A composition for diagnosing hypersensitivity immune diseases contains the antibody as an active ingredient. A kit for diagnosing hypersensitivity immune diseases contains the antibody as an active ingredient. A composition for preventing and treating hypersensitivity immune diseases contains the antibody as an active ingredient.
Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
BACKGROUND: In patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab 300 mg every 2 weeks can completely resolve nasal polys, sinus disease, and symptoms. In this case, patients ask for de-escalation. Although trials have demonstrated recurrence after stopping the biologic at 24 weeks, reducing the dose of dupilumab to once every 4 weeks did not result in deterioration of control. An extension of the treatment intervals would, however, diverge from the approval text, and is currently not recommended.
METHODS: The course of 29 patients with severe CRSwNP, type‑2 inflammation-associated comorbidities, and an indication for biologic was retrospectively analyzed. After resolution of CRSwNP and symptoms under biweekly dupilumab 300 mg, the dupilumab interval had been prolonged individually, initially up to 4 weeks, thereafter up to 6 weeks, if applicable. Control was assessed via quality of life (22-item sinonasal outcome test, SNOT-22), nasal polyp score, and smell identification test (Sniffin' Sticks; Burghart Messtechnik, Holm, Germany).
RESULTS: All patients showed an excellent improvement within the first 3 months. The dupilumab application interval was extended to 4 weeks after 7-31 months (median 13 months) and to 6 weeks (n = 9) after 17-35 months (median 23 months). No recurrent polyps or symptoms were subsequently observed.
CONCLUSION: In case of maximal regression of polyps and discomfort, extension of dupilumab injection intervals to 4 and potentially 6 weeks is possible without clinical worsening. Further studies on de-escalation or termination of biologic treatment when CRSwNP control is achieved are essential.
BACKGROUND: Hyperuricemia has placed an immense burden on the global healthcare system. Studies have discovered a close correlation between serum uric acid (SUA) and insulin resistance (IR). The objective of this investigation is to examine the association between the triglyceride-glucose (TyG) index, a simple surrogate for IR, and the presence of hyperuricemia.
METHODS: Between 2017 and 2021, an epidemiologic study was conducted on Royal Thai Army (RTA) personnel aged 35-60 years, involving a total of 231,286 participants. In the study, hyperuricemia was defined as a SUA level of 7 mg/dL and 6 mg/dL among male and female participants, respectively. Using linear regression analysis and logistic regression analysis, the association between the TyG index and SUA was determined.
RESULTS: A positive relationship was demonstrated between the TyG index and the SUA. Overall, SUA increased by 0.32 per unit of TyG index growth (95% CI: 0.31-0.32). In comparison with the first quartile, employees in the fourth TyG quartile had a greater likelihood of having hyperuricemia [adjusted odds ratio (AOR): 2.45, 95% CI: 2.38-2.52]. Effect modification by obesity on the association between the TyG index and SUA was observed (P-interaction < 0.001). Among individuals with obesity, compared with the first TyG index quartile, the AOR for hyperuricemia was 2.15 (95% CI: 2.06-2.25) and 2.14 (95% CI: 1.81-2.53) for the fourth quartile of the TyG index for males and females, respectively. However, for nonobese personnel, in comparison to the top quartile of the TyG index, the AOR for hyperuricemia was 2.73 (95% CI:2.61-2.84) and 5.03 (95% CI: 4.03-6.29) for the fourth quartile of the TyG index for males and females, respectively. Personnel in the fourth TyG index quartile revealed that the prevalence of hyperuricemia reached 44.2%.
CONCLUSION: A robust positive association between the TyG index and SUA was illustrated among active-duty RTA personnel. Obesity was identified as a modifier influencing this relationship. Furthermore, individuals in the fourth quarter of the TyG index, regardless of their obesity status, could be considered appropriate candidates for screening SUA levels.
The present invention relates to a novel composition of human recombinant antibody fragments in single-chain and Fab formats for completely neutralizing the venom of the scorpion Centruroides sculpturatus Ewing (C. sculpturatus). In particular, it discloses a novel composition of two antibody variant fragments, which can be in single chain (scFv) or Fab format. It comprises the scFv 10FG2 fragment (SEQ. ID. No: 1), which has broad cross-reactivity against several toxins from Mexican scorpion venoms, and the scFv LR fragment (SEQ. ID. No: 2), with more limited cross-reactivity. Also, it contains Fab 10FG2 (SEQ. ID. No: 3 and SEQ.ID. No: 4) and Fab LR (SEQ. ID. No: 5 and SEQ. ID. No: 6) fragments, characterized because its two antibody fragments recognize independent epitopes, present in the two main toxins of the scorpion C. sculpturatus, so they do not interfere with each other during their binding to them, thus complementing the neutralizing activity since requiring lower concentrati ons of both fragments to neutralize the poison, compared to the concentrations, required for either of them separately, eliminating the residual side effects that either of them allows, after the neutralization. The two scFv fragments showed affinities between 1.8X10-9 and 6.1X10-11 M. The scFv 10FG2 showed a better protective capacity in mice since it managed to neutralize up to 5 LD50 of the C. sculpturatus venom but with poisoning symptoms. Further, it comprises both scFvs in low molar ratios 1:5:5 (toxins: scFv 10FG2: scFv LR) to inhibit the toxic effect of the C. sculpturatus venom without showing symptoms of intoxication. Finally, the novel composition comprises the use of the two scFvs 10FG2 and LR (SEQ. ID. NO: 1 and SEQ. ID. NO: 2, respectively) or of the two Fab fragments 10FG2 and LR, which are complementary during the neutralization of the C. sculpturatus venom for preparing a novel composition capable of completely neutralizing the C. sculpturatus venom.
Placebo Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
A system is provided for providing simultaneous systolic and diastolic blood pressure measurements on multiple locations of a patient's body. The system according to the various embodiments can include a cluster, wherein the cluster comprises a plurality of blood pressure cuff devices. The system can also include a remote device. The remote device is associated with the cluster and connected to the plurality of blood pressure cuff devices of the cluster. The remote device also includes a user interface configured to initiate the simultaneous systolic and diastolic blood pressure measurements of the plurality of blood pressure cuff devices of the cluster. Furthermore, the system includes a storage system configured to receive data associated with the simultaneous systolic and diastolic blood pressure measurements of the plurality of blood pressure cuff devices of the cluster.
The invention relates to a medicament for treating the infantile anaphylactic cough, belonging to an internal Chinese medicinal preparation for treating the infantile anaphylactic cough. The medicament for treating the infantile anaphylactic cough is characterized in that one preparation of the medicament is prepared from the following Chinese medicinal raw materials: 10 grams of platycodon grandiflorus, 10 grams of willowleaf swallowwort rhizome, 6 grams of tangerine peel, 10 grams of aster tataricus, 10 grams of sessile stemona root, 6 grams of fineleaf schizonepeta herb, 6 grams of mix-fried ephedra, 10 grams of earthworm, 10 grams of periostracum cicada and 6 grams of liquorice. The medicament disclosed by the invention can be used for treating the infantile anaphylactic cough. One course of the treatment is formed by four days. Commonly, the patient can be cured by two courses of the treatment. The medicament has the advantages of obvious treatment effect, low cost and no toxic or side effects.
All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
A pharmaceutical composition for treating hypercholesterolemia is provided to maximize a treatment effect of hyperlipidemia by minimizing side effects caused by a HMG-CoA(3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor. A pharmaceutical composition for treating hypercholesterolemia comprises coenzyme Q 10, statin system drug, dissolution agent, surfactant, oil, antioxidant and pH adjusting agent. Nanoemulsion includes the coenzyme Q 10 and statin system drug in the same weight. The pH of nanoemulsion is controlled as 5.0-7.0 by comprising a pH adjusting agent of 0.1~5 weight% based on the whole weight of the nanoemulsion. The dissolution agent is polyethylene glycol, propylene glycol, triacetin, glycerol or diethylene glycol monoethyl ether. The oil is an oleic acid. The antioxidant is tocopherol, dibutyl hydroxytoluene, butyl-hydroxyanisol, ascorbic acid, sodium sulfite, sodium metabisulphite or sodium bisulfite. The pH adjusting agent is a citric acid, succinic acid, tartaric acid, formic acid or malic acid.
Participants will perform 3-4 exercise snacks (30-60s bursts of exercise) on at least 3 days of the week. The exercises prescribed in this arm will be designed to increase heart rate.
Approximately 800 subjects enrolled in this group will receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prev-nar13) and other RIV (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6 and 12 months of age. Subjects who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose will either receive PCV13 or PCV20 at 12 months of age (Visit 5).
The 2019 ADA-EASD clinical treatment guidelines recommend a GLP-1RA over basal insulin for patients with type 2 diabetes with suboptimal glycemic control despite metformin and a second-line glucose lowering agent. The basis of this recommendation is due to the side effect profiles of these two medications (i.e. reduced risk of hypoglycemia, some weight loss with GLP-1RA), convenience (once weekly injection) and the fact that the price of insulin has skyrocketed in recent years. Prior head-to-head randomized trials (EAGLE, LEAD 5) comparing select GLP-1RA and basal insulin have found mixed results. In EAGLE, adding either insulin glargine or liraglutide to patients with poorly controlled type 2 diabetes found no differences in the primary outcome (percentage of people reaching HbA1c \< 7%). In LEAD 5, liraglutide was associated with a slightly greater HbA1c reduction than glargine, however the dose of insulin was approximately 50% less than the dose used in EAGLE. The objective of this observational study is to describe the comparative effectiveness and safety of newly initiating a GLP1RA versus basal insulin in patients with type 2 diabetes using metformin and another oral glucose lowering medicine.
TIMOPTIC Ophthalmic Solution is available in concentrations of 0.25 and 0.5%. The usual starting dose is one drop of TIMOPTIC 0.25% in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% solution in the affected eye(s) twice a day.

Since in some patients the pressure-lowering response to TIMOPTIC may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with TIMOPTIC.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Dosages above one drop of TIMOPTIC 0.5% twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted. The concomitant use of two topical beta-adrenergic blocking agents is not recommended [see PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents].
One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
Background: Post-discharge pain remains a significant problem after many ambulatory surgery procedures. Both etoricoxib and gabapentin have been used to prevent postoperative pain; however their relative efficacy in the post-discharge period is not known. We hypothesized that daily use of etoricoxib would offer advantages over gabapentin as part of a multimodal analgesic regimen in the perioperative period due to its pharmacokinetic profile.

Methods: Seventy-five healthy outpatients undergoing elective ambulatory knee arthroscopy were randomly assigned to receive identical-appearing capsules containing either a placebo, gabapentin (1.2g, or etoricoxib 120 mg, 30-90 min before skin incision and at 08H00 on the first, second, and third postoperative days. Post-discharge pain was treated with "rescue" dipyrone syrup (500 mg). Pain intensity (as assessed using a 100 visual analog scale), dipyrone usage, and the incidence of nausea and vomiting, sedation and anxiety were recorded at specific time intervals in the postoperative period. The recovery of functional activity was assessed at 96 h after surgery using a validated questionnaire.
Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.
Moderate-Intensity Continuous Training (MICT) without Nutritional education. The MICT training consisted of 3 sessions per week in a cycle ergometer during 50 min at moderate intensity, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer.
BACKGROUND AND OBJECTIVE: Brivudine has been used in herpes zoster (HZ) treatment for years, but the safety and efficacy of brivudine are inconclusive. Here we perform a meta-analysis to assess the efficacy, safety, incidence of postherpetic neuralgia of brivudine.
METHODS: Data of randomized controlled Trials (RCTS) were obtained from the databases of both English (PubMed, Embase, and Cochrane Library) and Chinese (China National Knowledge Infrastructure, China Science Journal Database, and WanFang Database) literatures from inception to 12 September 2022. Meta-analyses of efficacy and safety of Brivudine for the treatment of herpes zoster for RCTS were conducted.
RESULTS: The analyses included seven RCTS (2095 patients in experimental group and 2076 patients in control group) in the treatment of HZ with brivudine. It suggested that the brivudine group was superior to the control group in terms of efficacy (p = .0002) and incidence of postherpetic neuralgia (p = .04). But the incidence of adverse reactions has no significant difference between the brivudine and the control groups (p = .22). In addition, subgroup analysis of adverse events also showed that brivudine was about the same safety as other modalities in the treatment of HZ (p > .05).
CONCLUSIONS: Brivudine is effective for HZ. However, the evidence on the safety of brivudine is insufficient.